By Anil Oza
November 11, 2026
In a milestone study that underscores the critical importance of diversity in genomic research, scientists have uncovered thousands of previously unidentified genetic variants that dictate how individuals respond to common prescription medications. The findings, published Wednesday in Science Translational Medicine, represent a significant leap forward in the field of pharmacogenomics—the study of how our DNA influences our reaction to drugs.
By leveraging the massive, diverse dataset provided by the National Institutes of Health’s (NIH) All of Us Research Program, researchers analyzed the genetic profiles of nearly 100,000 Americans. The results were striking: every single participant carried at least one genetic variant in the 16 "pharmacogenes" examined. Perhaps more urgently, the study found that one in four participants had been prescribed a medication that could be directly impacted by these genetic markers.
The Promise of Precision: Understanding Pharmacogenomics
Pharmacogenes are essentially the biological "gatekeepers" of medication efficacy. They encode the enzymes and proteins responsible for how the body metabolizes, transports, and responds to chemical compounds. When these genes harbor specific variants, the consequences can be profound.
For some, these variants mean a standard dose of a medication might be metabolized too slowly, leading to toxic side effects. For others, the drug might be cleared from the system so rapidly that it never reaches therapeutic levels, rendering the treatment effectively useless. These genetic differences affect a wide swath of common clinical treatments, including selective serotonin reuptake inhibitors (SSRIs) for depression, statins for cholesterol management, various chemotherapy regimens, and blood thinners like Plavix.
"If you have a prior experience with a medicine that did not work for you, or had a side effect, we can’t say it’s absolutely because of genetics," said Philip Empey, director of the Center for Clinical Pharmaceutical Sciences at the University of Pittsburgh and the senior author of the study. "But we are appreciating more and more that people are different, and genetics is one reason that may suggest where those differences come from."
Chronology of a Genomic Breakthrough
The road to this discovery has been paved by a shift in how genomic databases are constructed. Historically, large-scale genetic studies were overwhelmingly skewed toward populations of European ancestry. This bias created a "genomic gap," where diagnostic tools and drug guidelines developed from these studies often failed to accurately predict outcomes for people of African, Hispanic, Asian, or Indigenous descent.
- 2016: The 21st Century Cures Act is enacted, providing the initial bedrock of funding for the All of Us Research Program. The goal is established: collect comprehensive health and genetic data from 1 million Americans, with a specific focus on underrepresented communities.
- 2023: All of Us hits a critical mass of diverse genomic data, allowing researchers to begin comparative analyses that were impossible using older, less representative datasets like the U.K. Biobank.
- 2023-2024: The program expands its scope to include the pediatric population, aiming to secure data on how children metabolize medication.
- November 2026: The current study is released, confirming that the diversity of the All of Us cohort has successfully identified thousands of variants that remained invisible in previous, less diverse studies.
Supporting Data: Why Representation Matters
The data from the All of Us cohort is uniquely powerful because it does not just look at the presence of genes, but the nuance of how those genes vary across ancestral lines.
Previous research often relied on cohorts that lacked the granular detail required to see how rare variants cluster within specific populations. By including nearly 100,000 participants from varied backgrounds, the current study identified a "constellation of variants" that had been largely overlooked.
The inclusion of these variants is not merely academic; it is a clinical necessity. When a physician prescribes a medication based on "average" patient data, they are operating on an assumption that may not apply to a patient whose pharmacogenetic profile includes these newly discovered, ancestry-specific variants. As the study notes, identifying these markers is the first step toward creating clinical decision-support tools that provide physicians with actionable, real-time advice tailored to the patient sitting in the exam room.
The Path to Implementation: Hurdles in the Clinic
Despite the breakthrough, the transition from laboratory discovery to bedside practice faces a daunting list of obstacles.
"The paper points to the need to give more attention to the role genetics plays in the clinic," Empey explained. "But there are a number of barriers before these results can make their way into patient care."
The challenges are threefold:
- Infrastructure: Most patients still do not have their full genomes sequenced as part of their standard electronic health record (EHR).
- Physician Education: Many clinicians are not trained to interpret pharmacogenetic data or to understand which specific variants correspond to which drug-dosage adjustments.
- Complexity: Because there is not one "master gene" for drug response, but rather a complex interplay of many, integrating this data requires sophisticated software that can synthesize genetic information with clinical needs at the moment of prescription.
Official Responses and the Funding Crisis
The findings have been hailed by policy experts as a victory for health equity. Loren Saulsberry, a health policy researcher who has extensively studied equity in pharmacogenomics, praised the study’s impact.
"This really furthers the emerging evidence of how genetically guided clinical care adds benefit across a diverse population," said Saulsberry, who was not involved in the study. She noted that by building the foundation of precision medicine on a diverse dataset, researchers are actively working to prevent the widening of health disparities that often accompany new, high-cost medical technologies.
However, the future of this work is clouded by significant fiscal uncertainty. All of Us relies on a hybrid funding model: the 21st Century Cures Act and yearly Congressional appropriations. The former is set to expire in the 2027 fiscal year. While the program is slated to receive $122 million under current budget proposals, that figure represents an 80% reduction from its 2023 peak.
Joshua Denny, the former CEO of the program who recently transitioned to a leadership role at the University of Chicago, described the impact of these cuts as "dramatic."
"The engagement activities, the brick and mortar that we had enrolling at academic medical centers and FQHCs [Federally Qualified Health Centers] and mobile units—these kinds of things were cut back dramatically," Denny said.
The financial strain has forced the program to make difficult concessions, including pausing the return of genetic health-related results to participants—a feature that was once a core pillar of the program’s value proposition to the public.
Implications: The Future of Precision Health
The implications of the All of Us data extend far beyond the current study. The program’s expansion into pediatric data, currently involving 5,000 children, remains a vital, albeit vulnerable, component of the mission.
Sara Van Driest, director of pediatrics for All of Us, emphasized that while the data is promising, the long-term success of the project is contingent on consistent support. "In order to really enroll children at scale and build a dataset that’s going to fuel the future of precision health, we’re going to need stable funding in the years ahead," she said. "I should say, increased and stable funding in the years ahead."
As the medical community looks toward a future where "one size fits all" prescribing becomes a relic of the past, the work being done at All of Us serves as the primary engine of progress. By identifying the genetic variations that make us unique, the program is proving that precision medicine is only as precise as the population it represents. Whether that vision can be sustained in the face of dwindling resources remains the most critical question for the next decade of American health policy.
